In Vivo Molecular Imaging Biomarkers: Clinical Pharmacology's new “PET”?
Medicine, including the pharmaceutical and biotechnology industries as well as many clinical practitioners, has recognized the importance of using molecular imaging biomarkers, including those labeled in such a way as to be imaged by positron emission tomography (PET), as tools for predicting outcom...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2007-06, Vol.81 (6), p.792-795 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 795 |
|---|---|
| container_issue | 6 |
| container_start_page | 792 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 81 |
| creator | Nutt, R Vento, L J Ridinger, M H T |
| description | Medicine, including the pharmaceutical and biotechnology industries as well as many clinical practitioners, has recognized the importance of using molecular imaging biomarkers, including those labeled in such a way as to be imaged by positron emission tomography (PET), as tools for predicting outcomes in drug development and creating opportunities for “personalized” medicine, for diagnosing early‐stage disease, and for the follow‐up of the effectiveness of treatment.1 However, only one important and widely used PET biomarker is currently approved by the Food and Drug Administration (FDA). If the technology is so important, we can ask why there is such a limitation to the availability of these biomarkers.
Clinical Pharmacology & Therapeutics (2007) 81, 792–795. doi:10.1038/sj.clpt.6100213 |
| doi_str_mv | 10.1038/sj.clpt.6100213 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70506383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70506383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3733-2216fb565c11fe7950acadca115c4ab5e4fe373783c4da8745e818610b9330083</originalsourceid><addsrcrecordid>eNqFkE9PwjAYhxujEUTP3swu6mnQruvWeTG6oJJg5IBem650WOw2bJmEGx9EvxyfxBJmOHp68ybP--f3AHCOYBdBTHt21hV6vuhGCMIA4QPQRgQHfkQwOQRtCGHiJwGOWuDE2plrw4TSY9BCMYEkTFAbDAel96a-Ku-50lLUmhtvUPCpKqfevaoKbj6ksTdeqlWpBNfe6J2bgotKV9PVtfVKufQ26-9Rf7xZ_9yegqOcayvPmtoBrw_9cfrkD18eB-nd0Bc4xtgPAhTlGYmIQCiXcUIgF3wiOEJEhDwjMsylA2OKRTjhNA6JpIi6iFmCMYQUd8DVbu_cVJ-1tAtWKCuk1ryUVW1ZDAmMMMUO7O1AYSprjczZ3CgXasUQZFuBzM7YViBrBLqJi2Z1nRVysucbYw64bABunZDc8FIou-cojQISJI6Ld9xSabn67y5LR-O_F34Bm_yLVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70506383</pqid></control><display><type>article</type><title>In Vivo Molecular Imaging Biomarkers: Clinical Pharmacology's new “PET”?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Nutt, R ; Vento, L J ; Ridinger, M H T</creator><creatorcontrib>Nutt, R ; Vento, L J ; Ridinger, M H T</creatorcontrib><description>Medicine, including the pharmaceutical and biotechnology industries as well as many clinical practitioners, has recognized the importance of using molecular imaging biomarkers, including those labeled in such a way as to be imaged by positron emission tomography (PET), as tools for predicting outcomes in drug development and creating opportunities for “personalized” medicine, for diagnosing early‐stage disease, and for the follow‐up of the effectiveness of treatment.1 However, only one important and widely used PET biomarker is currently approved by the Food and Drug Administration (FDA). If the technology is so important, we can ask why there is such a limitation to the availability of these biomarkers.
Clinical Pharmacology & Therapeutics (2007) 81, 792–795. doi:10.1038/sj.clpt.6100213</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/sj.clpt.6100213</identifier><identifier>PMID: 17505491</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>New York, NY: Nature Publishing</publisher><subject>Biological and medical sciences ; Dideoxynucleosides - chemistry ; Dideoxynucleosides - pharmacokinetics ; Drug Approval ; Fluorine Radioisotopes ; Fluorodeoxyglucose F18 - chemistry ; Fluorodeoxyglucose F18 - pharmacokinetics ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Medical sciences ; Miscellaneous. Technology ; Misonidazole - chemistry ; Misonidazole - pharmacokinetics ; Molecular Structure ; Nitriles - chemistry ; Nitriles - pharmacokinetics ; Pharmacology, Clinical - methods ; Positron-Emission Tomography - methods ; Radiodiagnosis. Nmr imagery. Nmr spectrometry ; Radioisotopes - chemistry ; Radioisotopes - pharmacokinetics ; Radiopharmaceuticals - chemistry ; Radiopharmaceuticals - pharmacokinetics ; United States ; United States Food and Drug Administration</subject><ispartof>Clinical pharmacology and therapeutics, 2007-06, Vol.81 (6), p.792-795</ispartof><rights>2007 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3733-2216fb565c11fe7950acadca115c4ab5e4fe373783c4da8745e818610b9330083</citedby><cites>FETCH-LOGICAL-c3733-2216fb565c11fe7950acadca115c4ab5e4fe373783c4da8745e818610b9330083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1038%2Fsj.clpt.6100213$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1038%2Fsj.clpt.6100213$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18862529$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17505491$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nutt, R</creatorcontrib><creatorcontrib>Vento, L J</creatorcontrib><creatorcontrib>Ridinger, M H T</creatorcontrib><title>In Vivo Molecular Imaging Biomarkers: Clinical Pharmacology's new “PET”?</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Medicine, including the pharmaceutical and biotechnology industries as well as many clinical practitioners, has recognized the importance of using molecular imaging biomarkers, including those labeled in such a way as to be imaged by positron emission tomography (PET), as tools for predicting outcomes in drug development and creating opportunities for “personalized” medicine, for diagnosing early‐stage disease, and for the follow‐up of the effectiveness of treatment.1 However, only one important and widely used PET biomarker is currently approved by the Food and Drug Administration (FDA). If the technology is so important, we can ask why there is such a limitation to the availability of these biomarkers.
Clinical Pharmacology & Therapeutics (2007) 81, 792–795. doi:10.1038/sj.clpt.6100213</description><subject>Biological and medical sciences</subject><subject>Dideoxynucleosides - chemistry</subject><subject>Dideoxynucleosides - pharmacokinetics</subject><subject>Drug Approval</subject><subject>Fluorine Radioisotopes</subject><subject>Fluorodeoxyglucose F18 - chemistry</subject><subject>Fluorodeoxyglucose F18 - pharmacokinetics</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Medical sciences</subject><subject>Miscellaneous. Technology</subject><subject>Misonidazole - chemistry</subject><subject>Misonidazole - pharmacokinetics</subject><subject>Molecular Structure</subject><subject>Nitriles - chemistry</subject><subject>Nitriles - pharmacokinetics</subject><subject>Pharmacology, Clinical - methods</subject><subject>Positron-Emission Tomography - methods</subject><subject>Radiodiagnosis. Nmr imagery. Nmr spectrometry</subject><subject>Radioisotopes - chemistry</subject><subject>Radioisotopes - pharmacokinetics</subject><subject>Radiopharmaceuticals - chemistry</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9PwjAYhxujEUTP3swu6mnQruvWeTG6oJJg5IBem650WOw2bJmEGx9EvxyfxBJmOHp68ybP--f3AHCOYBdBTHt21hV6vuhGCMIA4QPQRgQHfkQwOQRtCGHiJwGOWuDE2plrw4TSY9BCMYEkTFAbDAel96a-Ku-50lLUmhtvUPCpKqfevaoKbj6ksTdeqlWpBNfe6J2bgotKV9PVtfVKufQ26-9Rf7xZ_9yegqOcayvPmtoBrw_9cfrkD18eB-nd0Bc4xtgPAhTlGYmIQCiXcUIgF3wiOEJEhDwjMsylA2OKRTjhNA6JpIi6iFmCMYQUd8DVbu_cVJ-1tAtWKCuk1ryUVW1ZDAmMMMUO7O1AYSprjczZ3CgXasUQZFuBzM7YViBrBLqJi2Z1nRVysucbYw64bABunZDc8FIou-cojQISJI6Ld9xSabn67y5LR-O_F34Bm_yLVQ</recordid><startdate>200706</startdate><enddate>200706</enddate><creator>Nutt, R</creator><creator>Vento, L J</creator><creator>Ridinger, M H T</creator><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200706</creationdate><title>In Vivo Molecular Imaging Biomarkers: Clinical Pharmacology's new “PET”?</title><author>Nutt, R ; Vento, L J ; Ridinger, M H T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3733-2216fb565c11fe7950acadca115c4ab5e4fe373783c4da8745e818610b9330083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Biological and medical sciences</topic><topic>Dideoxynucleosides - chemistry</topic><topic>Dideoxynucleosides - pharmacokinetics</topic><topic>Drug Approval</topic><topic>Fluorine Radioisotopes</topic><topic>Fluorodeoxyglucose F18 - chemistry</topic><topic>Fluorodeoxyglucose F18 - pharmacokinetics</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Medical sciences</topic><topic>Miscellaneous. Technology</topic><topic>Misonidazole - chemistry</topic><topic>Misonidazole - pharmacokinetics</topic><topic>Molecular Structure</topic><topic>Nitriles - chemistry</topic><topic>Nitriles - pharmacokinetics</topic><topic>Pharmacology, Clinical - methods</topic><topic>Positron-Emission Tomography - methods</topic><topic>Radiodiagnosis. Nmr imagery. Nmr spectrometry</topic><topic>Radioisotopes - chemistry</topic><topic>Radioisotopes - pharmacokinetics</topic><topic>Radiopharmaceuticals - chemistry</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nutt, R</creatorcontrib><creatorcontrib>Vento, L J</creatorcontrib><creatorcontrib>Ridinger, M H T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nutt, R</au><au>Vento, L J</au><au>Ridinger, M H T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vivo Molecular Imaging Biomarkers: Clinical Pharmacology's new “PET”?</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2007-06</date><risdate>2007</risdate><volume>81</volume><issue>6</issue><spage>792</spage><epage>795</epage><pages>792-795</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>Medicine, including the pharmaceutical and biotechnology industries as well as many clinical practitioners, has recognized the importance of using molecular imaging biomarkers, including those labeled in such a way as to be imaged by positron emission tomography (PET), as tools for predicting outcomes in drug development and creating opportunities for “personalized” medicine, for diagnosing early‐stage disease, and for the follow‐up of the effectiveness of treatment.1 However, only one important and widely used PET biomarker is currently approved by the Food and Drug Administration (FDA). If the technology is so important, we can ask why there is such a limitation to the availability of these biomarkers.
Clinical Pharmacology & Therapeutics (2007) 81, 792–795. doi:10.1038/sj.clpt.6100213</abstract><cop>New York, NY</cop><pub>Nature Publishing</pub><pmid>17505491</pmid><doi>10.1038/sj.clpt.6100213</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2007-06, Vol.81 (6), p.792-795 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70506383 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Biological and medical sciences Dideoxynucleosides - chemistry Dideoxynucleosides - pharmacokinetics Drug Approval Fluorine Radioisotopes Fluorodeoxyglucose F18 - chemistry Fluorodeoxyglucose F18 - pharmacokinetics Humans Investigative techniques, diagnostic techniques (general aspects) Medical sciences Miscellaneous. Technology Misonidazole - chemistry Misonidazole - pharmacokinetics Molecular Structure Nitriles - chemistry Nitriles - pharmacokinetics Pharmacology, Clinical - methods Positron-Emission Tomography - methods Radiodiagnosis. Nmr imagery. Nmr spectrometry Radioisotopes - chemistry Radioisotopes - pharmacokinetics Radiopharmaceuticals - chemistry Radiopharmaceuticals - pharmacokinetics United States United States Food and Drug Administration |
| title | In Vivo Molecular Imaging Biomarkers: Clinical Pharmacology's new “PET”? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A13%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vivo%20Molecular%20Imaging%20Biomarkers:%20Clinical%20Pharmacology's%20new%20%E2%80%9CPET%E2%80%9D?&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Nutt,%20R&rft.date=2007-06&rft.volume=81&rft.issue=6&rft.spage=792&rft.epage=795&rft.pages=792-795&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/sj.clpt.6100213&rft_dat=%3Cproquest_cross%3E70506383%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70506383&rft_id=info:pmid/17505491&rfr_iscdi=true |